Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal

Metastatic uveal melanoma has historically poor OS outcomes; tebentafusp set a high bar but only in HLA-A2+. Darovasertib+crizotinib shows encouraging Phase 2 response/PFS signals, but OS in Phase 3 is a stringent endpoint with crossover and small HLA-A2-negative population risks. Primary completion not until Jan 2027 adds disclosure timing risk. Combination biology is plausible but OS wins in UM remain rare.

Metastatic uveal melanoma has historically been refractory; OS endpoints in Phase 3 are tough to hit. Darovasertib+crizotinib showed encouraging Phase 2 ORR/PFS signals in HLA-A2-negative MUM (excluded from tebentafusp), supporting biological rationale. However, OS readouts often miss due to crossover, subsequent therapies, and modest effect sizes. Primary completion ~Jan 2027 with active-not-recruiting status suggests maturation pending. Base rate for positive Phase 3 OS in oncology ~30-40%.','

Phase 2/3 first-line trial in HLA-A2-negative metastatic uveal melanoma addresses high unmet need, and active-not-recruiting lowers enrollment risk. But Phase 3 overall survival is a stringent endpoint, no prior efficacy data are provided, and rare-disease OS readout/disclosure risk is meaningful.

Hard OS endpoint in metastatic uveal melanoma is a high bar. First-line HLA-A2-negative setting has unmet need and active-not-recruiting status lowers execution risk, but Phase 2/3 combo evidence and no supplied randomized prior data keep odds below even.

Registrational Phase 2/3 in a rare, high-unmet-need first-line metastatic uveal melanoma subgroup supports a plausible signal, and active-not-recruiting reduces execution risk. But Phase 3 overall survival is a hard endpoint with long follow-up and oncology OS trials often fail despite disease-control signals.

Phase 2/3 seamless design in rare HLA-A2-neg mUM with OS primary endpoint; active not recruiting status and 2027 completion imply limited mature prior combo efficacy data; oncology Ph3 success rates low in this indication with high attrition risk.

Phase 2/3 design in rare HLA-A2-neg metastatic uveal melanoma population; OS primary endpoint is high-quality but requires long follow-up to Jan 2027. Active not recruiting status implies supportive earlier data, yet small indication, novel combo, and typical oncology Phase 3 attrition plus readout/execution risks cap success odds below 50%.

Phase 2/3 trial with OS primary endpoint in HLA-A2-negative metastatic uveal melanoma; targeted darovasertib+crizotinib combo, active not recruiting, primary completion in 239 days; oncology OS endpoints carry high failure risk from statistical and execution challenges.

Prior phase 2 data for darovasertib plus crizotinib in metastatic uveal melanoma demonstrated encouraging efficacy signals. While OS is a rigorous Phase 3 endpoint, the lack of approved therapies for HLA-A2-negative MUM and strong mechanistic rationale provide a reasonable probability of success, roughly in line with average oncology Phase 3 success rates.

In April 2026, IDEAYA reported top-line data from the Phase 2/3 OptimUM-02 trial of darovasertib + crizotinib in HLA-A2-negative mUM. The combo showed immense PFS benefit (HR 0.42, p<0.0001) and 37.1% ORR vs 5.8% for control. An early positive OS trend was already noted. Given this profound efficacy in a disease with historically poor survival (~12 mo), Phase 3 OS success is highly probable.

Phase 2/3 OptimUM-02 recently reported highly positive PFS data (HR 0.42, p<0.0001) and ORR (37.1% vs 5.8%) against standard of care in first-line HLA-A2 negative metastatic uveal melanoma. Given the lack of effective subsequent therapies and an already-observed early positive OS trend, the Phase 3 OS analysis is highly likely to be positive. Market pricing at 34% vastly underestimates this.

Uveal melanoma is rare, OS endpoint requires large effect; prior data shows response but OS benefit uncertain. Phase 3 may be underpowered. Positive OS result probability ~30%.

Phase 2 data likely showed tumor responses, but OS in Phase 3 for metastatic uveal melanoma is challenging. Historical oncology Phase 3 OS success rate ~30-40%. Small patient pool, potential crossover, and aggressive disease lower odds. Estimate 35% probability of positive OS.

Phase 2 data showed median OS not reached and 1-year OS ~90% in first-line HLA-A2-negative patients, far exceeding historical benchmarks. Randomized Phase 3 design, fully enrolled, with OS as primary endpoint. High likelihood of positive result, but risk of dilution from crossover or lower effect size remains.

OS benefit in metastatic uveal melanoma is a high bar. Darovasertib+crizotinib showed promising ORR in early studies, but ORR rarely translates cleanly to OS in this aggressive disease. Phase 3 OS endpoint requires large effect or long follow-up; crossover and subsequent therapies can confound results. HLA-A2-negative enrichment helps but doesn't guarantee survival advantage. Probability of positive Phase 3 OS result is modest.

Phase 3 OS endpoint in metastatic uveal melanoma is challenging despite encouraging Phase 2 signals. Darovasertib+crizotinib targets PKC/MAPK pathway rationally, and early data showed promising ORR/PFS. However, OS benefit is harder to demonstrate in this aggressive disease with potential crossover and post-progression therapies. Historical Phase 3 oncology OS success ~35-45%.

OS benefit in metastatic uveal melanoma is a high bar despite promising PFS from darovasertib+crizotinib. HLA-A2-negative patients lack tebentafusp access, aiding control-arm differentiation, but crossover and subsequent therapies confound OS. Phase 2/3 design with OS primary is ambitious for this rare aggressive disease. ~31% chance of positive Phase 3 OS result.

Darovasertib/crizotinib showed strong PFS benefit in GEM-1. OS is the primary endpoint here. While OS can be confounded by crossover, the magnitude of PFS gain and mechanism support a positive OS outcome in this specific HLA-A2 neg population.

Darovasertib/crizotinib showed strong PFS benefit in G1348 (HR 0.45). OS data is immature but trended positive. HLA-A2 neg population excludes those eligible for tebentafusp, creating a clear unmet need. Phase 3 design leverages robust Phase 2 signals, though OS endpoints in melanoma carry execution risk.

Darovasertib plus crizotinib shows robust Phase 2 efficacy in metastatic uveal melanoma. Targeting HLA-A2-negative patients addresses a clear unmet need where tebentafusp is ineffective. First-line setting improves outcomes. OS remains stringent due to crossover risk, but enrollment is complete, reducing operational uncertainty. Intrinsic YES ~52%.

The trial is a combined Phase 2/3 study of darovasertib plus crizotinib in a rare, aggressive HLA‑A2‑negative metastatic uveal melanoma population. No prior efficacy data are disclosed, and overall survival is a high bar for first‑line therapy. Early‑phase combination risk and difficult disease suggest modest chance of a positive OS outcome.

The trial is a Phase 2/3 study in a rare, aggressive cancer (HLA‑A2‑negative metastatic uveal melanoma) with overall survival as the primary endpoint. The combination of darovasertib, a PKC inhibitor, and crizotinib, an ALK/MET inhibitor, has limited early data and faces high efficacy bar for OS. Enrollment is complete but the disease’s poor prognosis and lack of strong mechanistic rationale lower the chance of a clear survival benefit.

The trial is a combined Phase 2/3 first‑line study of darovasertib plus crizotinib in a rare HLA‑A2‑negative metastatic uveal melanoma cohort. Early PKC/MET inhibition data suggest disease control, but overall‑survival gains in this indication have historically been modest. The OS endpoint is hard and the patient pool is small, raising operational and statistical risk. Thus we estimate a ~40 % intrinsic chance of a positive OS result.

The trial targets a rare, aggressive HLA‑A2‑negative metastatic uveal melanoma. It is a Phase 2/3 first‑line study of a novel agent plus crizotinib with no published efficacy data. Early‑stage combination trials in this indication have historically low OS benefit, and the study is not yet recruiting, adding operational uncertainty.

Phase 2/3 design with OS primary endpoint in rare orphan indication (HLA-A2-negative mUM). Uveal melanoma has historically poor immunotherapy response. Darovasertib (PKC inhibitor) plus crizotinib (c-MET/ALK) is mechanistically plausible but prior Phase 1/2 data in broader mUM showed modest activity. Active Not Recruiting status with 236 days to primary completion suggests enrollment complete but no early efficacy signals disclosed. OS benefit in first-line setting against standard care is high bar. Disclosure risk: no interim readouts pre-specified in public records.

Uveal melanoma has poor historical immunotherapy response, especially HLA-A2-negative subset. Phase 2/3 design with OS endpoint in rare cancer is high-risk. No prior registrational data for darovasertib+crizotinib combo. Active Not Recruiting status suggests enrollment challenges. OS benefit in first-line setting against standard care is ambitious with 238 days to completion.

HLA-A2-negative metastatic uveal melanoma is an ultra-rare, aggressive tumor with historically poor immunotherapy responses. OS endpoint in Phase 3 requires large, prolonged follow-up; trial is Phase 2/3 with only 239 days to primary completion, suggesting immature data. Prior darovasertib monotherapy showed limited efficacy in this population. Combination with crizotinib (c-MET/ALK inhibitor) lacks strong mechanistic rationale in uveal melanoma. Active Not Recruiting status raises concern about enrollment or futility. Disclosure risk of early termination or negative interim is material.

Metastatic uveal melanoma is a high-mortality indication with limited effective therapies. The Phase 2/3 design tests darovasertib+crizotinib in HLA-A2-negative patients, a specific subset. OS endpoint is rigorous. Prior darovasertib data showed some activity but survival gains in this aggressive cancer are historically modest. Trial is ongoing but not yet recruiting, indicating execution risk. Given indication difficulty and stringent OS endpoint, intrinsic YES odds appear sub-50%.

HLA-A2-negative metastatic uveal melanoma is an aggressive orphan indication with poor baseline prognosis (12-18 month median OS). The darovasertib-crizotinib combination targets PKC and MET pathways with scientific rationale. Biomarker-selected first-line population improves mechanistic targeting. Phase 2/3 adaptive design reduces phase 3 failure risk. However, OS endpoint is stringent, and patient population is small due to HLA-A2 exclusion (~50% of patients). First-line OS benefit over standard of care is historically difficult in this indication, even with targeted approaches. Sponsor IDEY

Phase 3 overall survival is a rigorous endpoint; historically ~30‑40% of oncology trials succeed. Darovasertib + crizotinib targets a rare HLA‑A2‑negative population with high unmet need, but prior data are limited and mechanism is novel. Small patient pool raises enrollment risk and may limit statistical power, increasing uncertainty.